Doctors and medical researchers are busy all the time in inventing and finding new ways to save us against diseases and now the Tulane University researchers played their part in this regard and developed a new drug that is effective against malaria if it is not at the severe stage. This information is according to the results from a FDA-supervised clinical trial published in the latest issue of The Lancet Infectious Diseases.
And the good and positive part is that the results are noteworthy as the health experts have long warned that the parasite responsible for most malaria cases, Plasmodium falciparum, is developing confrontation to widely used treatments. New medications are needed to build up secondary resistances against drug-resistant strains of the parasite.
The medicine or drug which is called AQ-13 was competent to clear the parasite accountable for the disease within a week, similar the value of the most widely used treatment regimen.
Senior author and professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine Dr. Donald Krogstad said: “The clinical trial results are extraordinary encouraging. Compared to the current first-line recommendation for treatment of malaria, the new drug comes out very well.”
Mosquitoes infected by a parasite and then spread malaria and 200 million illness across the globe is caused by malaria and more than 400, 000 deaths annually because of this disease. Chloroquine was used for malaria for decades until Plasmodium falciparum developed resistance. And a combination of drug, artemether, and lumefantrine is the main cure for malaria even though resistance is also developing to the drug combination in some countries.
Researchers recruited 66 adult men in Mali with uncomplicated malaria, which is defined as malaria that is not dangerous to life. Half were treated with new drug AQ-13 and the remaining received artemether and lumefantrine. Both of these drugs have same results. Researchers hope to widespread testing of this drug to more participants and they want to include men, women, and children before they recommend this drug widely as new and reliable treatment.
Dr. Donald said: “The potential long-term implications are bigger than one drug. The conceptual step here is that if you understand the resistance well enough, you may actually be able to develop others as well. We synthesized over 200 analogues and of those, 66 worked against the resistant parasites.”